Related Experiment Videos
Botulinum toxin type B for treatment of spasmodic dysphonia: a case report
Robert Thayer Sataloff1, Yolanda D Heman-Ackah, Lance L Simpson
1Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Phillyent.com
Journal of Voice : Official Journal of the Voice Foundation
|October 25, 2002
Abstract:
Although treatment with botulinum toxin type A (BTXA) has become the standard of care for most patients with laryngeal dystonia, its use is limited by the development of resistance to the toxin in some patients. Botulinum toxin type B (BTXB) has been found to be safe and effective in the treatment of cervical dystonia, but it has not been used previously to treat spasmodic dysphonia. Our experience with BTXB in a patient who developed resistance to BTXA suggests that BTXB may be safe and effective for the treatment of laryngeal dystonia, as well.